Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Pravastatin for Pregnant Patients with Preeclampsia or Intrauterine Growth Restriction

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying two pregnancy-related conditions: preeclampsia and intrauterine growth restriction (IUGR). Preeclampsia is a condition characterized by high blood pressure during pregnancy, which can lead to serious complications for both the mother and baby. Intrauterine growth restriction refers to a condition where the baby grows slower than expected in the womb. The study will use a medication called Pravastatin, which is commonly used to lower cholesterol, to see if it can help manage these conditions during pregnancy.

The purpose of the study is to determine if taking 40 mg of Pravastatin daily can help prolong pregnancy in women diagnosed with severe early-onset preeclampsia or IUGR between 24 and 29 weeks of gestation. Participants in the study will be randomly assigned to receive either Pravastatin or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor the duration of pregnancy from the time of inclusion until delivery.

Participants will take the medication orally in the form of a tablet. The study aims to provide insights into whether Pravastatin can be an effective treatment strategy for managing these conditions and potentially improving outcomes for both mothers and their babies. The trial is expected to continue until the end of 2027, with recruitment starting in 2025.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the trial, you will be informed about the study's purpose and procedures. You will be asked to provide informed consent, confirming your understanding and willingness to participate.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility. This includes verifying that you are between 24+0 to 29+6 weeks of pregnancy and have a diagnosis of severe early-onset preeclampsia or intrauterine growth restriction.

  3. Step 3

    Medication administration

    If eligible, you will be randomly assigned to receive either a 40 mg pravastatin tablet or a placebo. The tablet is to be taken orally once daily.

    The purpose of the medication is to assess its effect on prolonging the duration of pregnancy compared to standard management.

  4. Step 4

    Ongoing monitoring

    Throughout the trial, regular monitoring will be conducted to track your health and the progress of your pregnancy. This may include physical examinations, blood tests, and ultrasound scans.

    The monitoring aims to ensure your safety and gather data on the trial's primary endpoint, which is the number of days the pregnancy is prolonged.

  5. Step 5

    Completion of the trial

    The trial will conclude at the time of delivery. The primary outcome measured will be the duration of pregnancy from the time of inclusion in the study until delivery.

    After the trial, you may be asked to participate in follow-up assessments to gather additional data on the outcomes of the treatment.

Who can join the trial?

5 criteria

  • Must be pregnant with a single baby.
  • Pregnancy must be between 24 weeks and 29 weeks and 6 days.
  • Must have early-onset severe preeclampsia (PE): This means having high blood pressure and other symptoms during pregnancy, but not needing immediate delivery according to the doctor's assessment.
  • And/or must have intrauterine growth restriction (IUGR): This means the baby is smaller than expected for the number of weeks of pregnancy, with specific blood flow issues in the umbilical cord.
  • Must be able to give informed consent: This means understanding the study and agreeing to participate.

Who cannot join the trial?

5 criteria

  • Individuals who are not pregnant cannot participate.
  • Only females are eligible; males cannot participate.
  • Participants must be between 24.0 and 29.6 weeks of pregnancy.
  • Individuals with conditions other than intrauterine growth restriction (a condition where the baby grows slower than expected in the womb) or preeclampsia (a pregnancy complication characterized by high blood pressure) are excluded.
  • Participants must not belong to any vulnerable population groups that are not specified in the trial.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Pravastatin is a medication that is being tested in this clinical trial. It is usually used to lower cholesterol levels in people with high cholesterol. In this study, it is being given to pregnant individuals who have a condition called placental insufficiency, which means the placenta is not working as well as it should. The goal is to see if taking pravastatin can help prolong the pregnancy, giving the baby more time to grow and develop before birth. This is important because the condition can lead to complications for both the mother and the baby if the pregnancy ends too early.

What is already known about the treatment

Pravastatin – Pravastatin is taken orally in the form of a pill. It is currently being studied in clinical trials for its potential use in pregnant individuals experiencing severe early-onset placental insufficiency, specifically conditions like intrauterine growth restriction and preeclampsia. The main goal of using pravastatin in this context is to help prolong pregnancy duration. At the molecular level, pravastatin works by inhibiting an enzyme involved in cholesterol production, which may improve blood flow to the placenta. It is classified as a statin, a type of medication commonly used to lower cholesterol levels.

Investigated diseases

  • Intrauterine Growth Restriction

    Intrauterine Growth Restriction (IUGR) is a condition where a fetus is smaller than expected for the number of weeks of pregnancy. It occurs when the fetus does not grow at the normal rate inside the womb. This can result from various factors, including problems with the placenta, maternal health issues, or genetic conditions. As the pregnancy progresses, the fetus may continue to grow at a slower rate than normal. IUGR can lead to a baby being born with a low birth weight. The condition requires careful monitoring to ensure the health and well-being of both the mother and the fetus.

  • Preeclampsia

    Preeclampsia is a pregnancy-related condition characterized by high blood pressure and often protein in the urine. It typically occurs after the 20th week of pregnancy. The condition can lead to complications for both the mother and the baby if not managed properly. As preeclampsia progresses, it may cause swelling, sudden weight gain, and headaches. The exact cause of preeclampsia is not fully understood, but it involves abnormal development of blood vessels in the placenta. Monitoring and management are crucial to prevent further complications.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519853-12-00Protocol codeIIBSP-PRE-2024-198Estimated enrolment154 patientsSponsorFundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.